Third-line hormonal therapy to treat prostate cancer relapse after initial and second-line hormonal therapy: Report of 52 cases and literature review

Kazuhiro Matsumoto, Masayuki Hagiwara, Nozomi Hayakawa, Nobuyuki Tanaka, Yujiro Ito, Takahiro Maeda, Akiharu Ninomiya, Hirohiko Nagata, So Nakamura

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The aim of this study was to evaluate the efficacy of third-line combined androgen blockade (CAB) therapy for castration-resistant prostate cancer that relapsed after primary and second-line CAB. We retrospectively reviewed the medical records of 52 patients who received first-, second-, and third-line CAB therapy (medical or surgical castration, plus steroidal antiandrogen of chlormadinone acetate, or nonsteroidal antiandrogen of flutamide or bicalutamide). For cumulative analysis, we searched the PubMed database and identified a total of 50 cases published in English. Including our cases, this provided a total of 102 cases for analysis. In our study cohort, 11 cases (21.2%) achieved more than 50% reduction of serum prostate-specific antigen (PSA) on initiation of third-line CAB. We found that third-line CAB with nonsteroidal antiandrogen after second-line CAB with steroidal antiandrogen exhibited favorable results, with a positive response in six of 13 patients (46.2%). Cumulative analysis findings were comparable. Regarding the timing of third-line CAB administration, 15 patients had started at a PSA equal to or less than 4.0 ng/ml, and eight of them (53.3%) showed a positive response to treatment, compared to only three of 37 patients (8.1%) whose PSA at the initiation of third-line therapy was higher than 4.0 ng/ml (p<0.001). We conclude that third-line CAB with nonsteroidal antiandrogen would be particularly useful for patients whose cancer progressed after second-line CAB with steroidal antiandrogen. The timing of treatment seems to be important because the higher the PSA at the start of third-line therapy, the lower the PSA response rate.

Original languageEnglish
Pages (from-to)3645-3649
Number of pages5
JournalAsian Pacific Journal of Cancer Prevention
Volume15
Issue number8
DOIs
Publication statusPublished - 2014

Keywords

  • Alternative antiandrogen
  • CRPC
  • Hormonal therapy
  • Prostate cancer

ASJC Scopus subject areas

  • Epidemiology
  • Oncology
  • Public Health, Environmental and Occupational Health
  • Cancer Research

Fingerprint Dive into the research topics of 'Third-line hormonal therapy to treat prostate cancer relapse after initial and second-line hormonal therapy: Report of 52 cases and literature review'. Together they form a unique fingerprint.

  • Cite this